Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine—The monoclonal antibodies and gepants
Chia‐Chun Chiang, Todd J. Schwedt
Progress in brain research (2020), pp. 143-170
Closed Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials
Richard B. Lipton, Andrew Blumenfeld, Christopher Jensen, et al.
Cephalalgia (2023) Vol. 43, Iss. 2
Open Access | Times Cited: 31
Antagonism of CGRP Receptor: Central and Peripheral Mechanisms and Mediators in an Animal Model of Chronic Migraine
Rosaria Greco, Chiara Demartini, Miriam Francavilla, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 3092-3092
Open Access | Times Cited: 33
The state-of-the-art pharmacotherapeutic options for the treatment of chronic non-cancer pain
Ryan S. D’Souza, Brendan Langford, Rachel Wilson, et al.
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 7, pp. 775-789
Closed Access | Times Cited: 29
Potential treatment targets for migraine: emerging options and future prospects
Chia‐Chun Chiang, Frank Porreca, Carrie E. Robertson, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 3, pp. 313-324
Closed Access | Times Cited: 8
Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial
Richard B. Lipton, Alexandra Thiry, Beth Morris, et al.
Journal of Pain Research (2024) Vol. Volume 17, pp. 2431-2441
Open Access | Times Cited: 7
Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
Chia‐Chun Chiang, Todd J. Schwedt, Gina Dumkrieger, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 64, Iss. 9, pp. 1094-1108
Closed Access | Times Cited: 6
Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society
Hans‐Christoph Diener, Messoud Ashina, Isabelle Durand‐Zaleski, et al.
Cephalalgia (2021) Vol. 41, Iss. 3, pp. 279-293
Open Access | Times Cited: 29
Study of the structural features and solvent effects using ab initio molecular dynamics and energy decomposition analysis of atogepant in water and ammonia
T. Pooventhiran, Bhavya Gangadharappa, Ola A. Abu Ali, et al.
Journal of Molecular Liquids (2022) Vol. 352, pp. 118672-118672
Closed Access | Times Cited: 22
Association between serum vitamin D and severe headache or migraine: A population-based analysis
Suping Hao, Renyi Qian, Yiru Chen, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0313082-e0313082
Open Access
Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine
Mengyi Li, Siyong Huang, Jiabao Li, et al.
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 1231-1247
Open Access
Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
Pepa Polavieja, Mark Belger, Shiva Kumar Venkata, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 17
Calcitonin gene-related peptide in pathophysiology of migraine
A. V. Romanenko, V. V. Murzo, K.A. Popovskaya, et al.
Russian Journal of Pain (2024) Vol. 22, Iss. 2, pp. 56-56
Closed Access | Times Cited: 3
Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
Taoufik Alsaadi, Suzan Noori, Razmig Varakian, et al.
BMC Neurology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 14
Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review
Meghana Reddy Muddam, Omobolanle A Obajeun, Abdelrahman Abaza, et al.
Cureus (2023)
Open Access | Times Cited: 7
Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide [Part 1]: biology, pharmacology, and new insights into their cellular basis of action/signaling which are providing new therapeutic targets
Terry W. Moody, Robert T. Jensen
Current Opinion in Endocrinology Diabetes and Obesity (2021) Vol. 28, Iss. 2, pp. 198-205
Open Access | Times Cited: 16
Serum Calcitonin Gene-Related Peptide α and β Levels are Increased in COVID-19 Inpatients
Gabriel Gárate, Marta Pascual, Montserrat Rivero, et al.
Archives of Medical Research (2022) Vol. 54, Iss. 1, pp. 56-63
Open Access | Times Cited: 12
Migraine and Its Treatment from the Medicinal Chemistry Perspective
Ezgi Pehlivanlar, Simone Carradori, Rahime Şimşek
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 4, pp. 951-966
Open Access | Times Cited: 2
Emerging and future directions of migraine research and treatment
Chia‐Chun Chiang, David W. Dodick
Handbook of clinical neurology (2024), pp. 583-597
Closed Access | Times Cited: 2
Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment
Rajinder Bhardwaj, Mary Donohue, Jennifer Madonia, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 7
Open Access | Times Cited: 2
Currently Available Interventions for the Management of Migraine Pain
Rakesh K. Singh, Shivam Kumar Pandey, Shreya Singh, et al.
(2024), pp. 191-227
Closed Access | Times Cited: 2
First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients
Yang Zhao, Xiaodan Wang, Mengyue Niu, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Mass balance and pharmacokinetic characterization of zavegepant in healthy male subjects
Rajinder Bhardwaj, Mary Donohue, Jennifer Madonia, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 10
Open Access | Times Cited: 2
Effects of multiple‐dose administration of zavegepant nasal spray on the single‐dose pharmacokinetics of ethinyl estradiol‐levonorgestrel
Rajinder Bhardwaj, Julie L. Collins, Jennifer Madonia, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 65, Iss. 1, pp. 14-23
Open Access | Times Cited: 2
Combining two CGRP inhibitors to treat migraine
Lanfranco Pellesi
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 9, pp. 1135-1136
Closed Access | Times Cited: 10
Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open‐Label, Single‐Dose, Parallel‐Group Study
Rajinder Bhardwaj, Andrea Ivans, Joseph Stringfellow, et al.
Clinical Pharmacology in Drug Development (2023) Vol. 12, Iss. 8, pp. 790-800
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top